Skip to main content
AAPL+0.64%MSFT+1.07%NVDA+0.64%GOOGL+0.80%AMZN+1.46%SPCX+1.27%TSM+0.81%AVGO+3.64%META+0.81%TSLA+0.74%LLY-2.33%WMT-0.13%AMD+5.31%SKHY-0.11%JPM-1.77%BRK-B-2.07%MU+1.55%V-0.37%JNJ-2.15%XOM-3.97%MA-0.37%ASMLa+1.94%ABBV-2.33%COST-1.21%1398.HK-0.79%KO-0.71%0700.HK-6.57%CVX-4.74%PG-0.83%CSCO+2.18%0939.HK-0.05%ORCL-0.97%3988.HK-0.60%GE+0.52%BAC-1.07%HD-0.40%1816.HK-26.91%0857.HK-2.43%UNH-10.21%1288.HK-1.49%PM-0.85%0005.HK-2.10%NVS-2.46%INTC-0.91%HSBA.L-2.00%MS-1.29%AMAT+0.88%AP2d+2.23%AZN-1.93%TXN-1.16%AUDJPY-1.55%AUDUSD-1.47%AUDNZD-0.89%AUDCAD-0.88%EURAUD+0.88%AUDCHF-0.85%GBPAUD+0.82%GBPJPY-0.73%EURJPY-0.70%CHFJPY-0.69%CADJPY-0.68%NZDJPY-0.68%USDCHF+0.64%GBPUSD-0.63%USDCAD+0.60%EURUSD-0.60%NZDUSD-0.58%AUDSGD-0.52%USDZAR+0.45%AUDDKK-0.43%GBPTRY+0.41%USDTHB+0.34%GBPHKD+0.32%AUDNOK-0.32%NZDMXN+0.31%USDMXN+0.30%EURZAR+0.29%GBPMXN-0.28%USDNOK+0.28%GBPZAR+0.27%USDSEK+0.22%USDTRY+0.21%USDPLN+0.21%EURCNH-0.19%CHFNOK+0.19%EURHKD-0.16%USDILS+0.16%USDDKK+0.16%NOKJPY-0.16%CHFSEK+0.13%EURNOK+0.12%USDCNH-0.11%NZDSGD+0.10%USDJPY-0.10%GBPSGD-0.10%EURSGD-0.09%PLNJPY-0.08%USDSGD+0.07%EURSEK+0.07%SGDJPY+0.06%GBPNZD-0.06%GBPCAD-0.06%EURPLN+0.05%EURGBP+0.04%EURCHF+0.04%USDCOP-0.04%EURCZK+0.04%CADCHF+0.04%NZDCHF+0.03%EURNZD-0.03%CHFSGD-0.03%USDHKD-0.01%EURCAD0.00%GBPCHF0.00%EURDKK0.00%NZDCAD0.00%XPTUSD-0.79%XNGUSD-0.60%W1-0.51%C1-0.44%GAGUSD-0.42%XAGUSD-0.42%XAUUSD-0.41%GAUUSD-0.41%UKOIL+0.32%S1-0.26%HG1-0.23%COTTON+0.06%BTCUSD-2.93%ETHUSD+57.77%USDTUSD-0.01%XRPUSD+52.58%SOLUSD+57.55%TRXUSDT+0.87%ZECUSDT-5.74%XMRUSDT-1.64%DOGEUSD+55.95%LINKUSD-2.67%XLMUSD-3.27%BCHUSDT-3.03%LTCUSD+47.50%UNIUSD-2.22%SUIUSD-2.19%TONUSD+59.18%HBARUSDT-4.63%TAOUSDT-2.21%AAVEUSD-2.73%ONDOUSDT-4.04%ICPUSDT-1.70%DOTUSDT-3.23%WLDUSDT-2.82%ARBUSDT-5.08%ATOMUSDT-1.71%INJUSDT-6.68%STXUSDT-1.68%PYTHUSDT+0.83%TIAUSDT-2.26%FETUSDT-3.86%JUPUSDT+1.39%SEIUSDT-2.00%GRTUSDT-2.94%OPUSDT-2.63%IOTAUSDT-1.90%POLUSDT-1.51%WIFUSDT-2.25%AXSUSDT-2.18%EOSUSDT-3.74%IMXUSDT-3.36%FARTCOINUSDT-5.88%GALAUSDT-1.65%DYDXUSDT-2.17%ORDIUSDT-1.79%NOTUSDT-0.74%RONINUSDT-2.92%AAPL+0.64%MSFT+1.07%NVDA+0.64%GOOGL+0.80%AMZN+1.46%SPCX+1.27%TSM+0.81%AVGO+3.64%META+0.81%TSLA+0.74%LLY-2.33%WMT-0.13%AMD+5.31%SKHY-0.11%JPM-1.77%BRK-B-2.07%MU+1.55%V-0.37%JNJ-2.15%XOM-3.97%MA-0.37%ASMLa+1.94%ABBV-2.33%COST-1.21%1398.HK-0.79%KO-0.71%0700.HK-6.57%CVX-4.74%PG-0.83%CSCO+2.18%0939.HK-0.05%ORCL-0.97%3988.HK-0.60%GE+0.52%BAC-1.07%HD-0.40%1816.HK-26.91%0857.HK-2.43%UNH-10.21%1288.HK-1.49%PM-0.85%0005.HK-2.10%NVS-2.46%INTC-0.91%HSBA.L-2.00%MS-1.29%AMAT+0.88%AP2d+2.23%AZN-1.93%TXN-1.16%AUDJPY-1.55%AUDUSD-1.47%AUDNZD-0.89%AUDCAD-0.88%EURAUD+0.88%AUDCHF-0.85%GBPAUD+0.82%GBPJPY-0.73%EURJPY-0.70%CHFJPY-0.69%CADJPY-0.68%NZDJPY-0.68%USDCHF+0.64%GBPUSD-0.63%USDCAD+0.60%EURUSD-0.60%NZDUSD-0.58%AUDSGD-0.52%USDZAR+0.45%AUDDKK-0.43%GBPTRY+0.41%USDTHB+0.34%GBPHKD+0.32%AUDNOK-0.32%NZDMXN+0.31%USDMXN+0.30%EURZAR+0.29%GBPMXN-0.28%USDNOK+0.28%GBPZAR+0.27%USDSEK+0.22%USDTRY+0.21%USDPLN+0.21%EURCNH-0.19%CHFNOK+0.19%EURHKD-0.16%USDILS+0.16%USDDKK+0.16%NOKJPY-0.16%CHFSEK+0.13%EURNOK+0.12%USDCNH-0.11%NZDSGD+0.10%USDJPY-0.10%GBPSGD-0.10%EURSGD-0.09%PLNJPY-0.08%USDSGD+0.07%EURSEK+0.07%SGDJPY+0.06%GBPNZD-0.06%GBPCAD-0.06%EURPLN+0.05%EURGBP+0.04%EURCHF+0.04%USDCOP-0.04%EURCZK+0.04%CADCHF+0.04%NZDCHF+0.03%EURNZD-0.03%CHFSGD-0.03%USDHKD-0.01%EURCAD0.00%GBPCHF0.00%EURDKK0.00%NZDCAD0.00%XPTUSD-0.79%XNGUSD-0.60%W1-0.51%C1-0.44%GAGUSD-0.42%XAGUSD-0.42%XAUUSD-0.41%GAUUSD-0.41%UKOIL+0.32%S1-0.26%HG1-0.23%COTTON+0.06%BTCUSD-2.93%ETHUSD+57.77%USDTUSD-0.01%XRPUSD+52.58%SOLUSD+57.55%TRXUSDT+0.87%ZECUSDT-5.74%XMRUSDT-1.64%DOGEUSD+55.95%LINKUSD-2.67%XLMUSD-3.27%BCHUSDT-3.03%LTCUSD+47.50%UNIUSD-2.22%SUIUSD-2.19%TONUSD+59.18%HBARUSDT-4.63%TAOUSDT-2.21%AAVEUSD-2.73%ONDOUSDT-4.04%ICPUSDT-1.70%DOTUSDT-3.23%WLDUSDT-2.82%ARBUSDT-5.08%ATOMUSDT-1.71%INJUSDT-6.68%STXUSDT-1.68%PYTHUSDT+0.83%TIAUSDT-2.26%FETUSDT-3.86%JUPUSDT+1.39%SEIUSDT-2.00%GRTUSDT-2.94%OPUSDT-2.63%IOTAUSDT-1.90%POLUSDT-1.51%WIFUSDT-2.25%AXSUSDT-2.18%EOSUSDT-3.74%IMXUSDT-3.36%FARTCOINUSDT-5.88%GALAUSDT-1.65%DYDXUSDT-2.17%ORDIUSDT-1.79%NOTUSDT-0.74%RONINUSDT-2.92%
UT

United Therapeutics Corporation (UTHR)

NASDAQ • Healthcare

$577.34
-$6.75 (-1.2%)
Market closed

Last close at November 18, 2026 at 21:00 UTC

Open$581.43
Day Range$569.34 - $588.43
Avg. Volume (3M)518.4K
Market Cap$24.5B
P/E Ratio20.2
52 Week Range
$455.63$614.23

Metrics Over Time

Where the Money Goes

Q3 2026
Revenueeverything earned$832.5M100%
Gross Profitminus cost of goods$733.4M88%
Operating Incomeminus R&D and overhead$307.8M37%
Net Incomeminus taxes and the rest$258.6M31%

In plain terms: out of every $100 in revenue, United Therapeutics Corporation keeps $31 as net profit.

Fundamentals & Financials

Revenue (TTM)
$3.1B
Net Income (TTM)
$1.2B
EPS (TTM)
$28.56
ROA (TTM)
17.5%
Current Ratio
4.61

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

-16.9%Q2 2026$5.82
+6.0%Q3 2026$7.27
-5.0%Q4 2026$5.71

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q4 2026
Miss -5.0%

United Therapeutics trailed consensus on EPS but topped expectations on revenue in the third fiscal quarter of 2026, reported November 4, 2026, as revenue rose 4.1% to about $832.5 million (up from roughly $799.5 million a year ago) while EPS of $5.71 came in below the $6.01 estimate (-5%) even as revenue of $832.5 million topped the $781.1 million estimate (+6.6%). Profitability remained high, with gross margin at ~88% and operating margin at ~37%, alongside gross profit of roughly $733 million and operating income of about $307.8 million. Net income fell 23.6% year over year to about $258.6 million (down from roughly $338.7 million), consistent with the year-over-year decline in EPS of -20.3% from $7.16. The company generated operating cash flow of about $306.5 million and repurchased about $500.0 million of stock during the quarter. For the next period, consensus calls for EPS of $6.91 on revenue of $837.8 million.

View full earnings history

About United Therapeutics Corporation

United Therapeutics Corporation is a NASDAQ-listed biotechnology company focused on discovering, developing, and bringing to market therapies for chronic and severe illnesses, especially pulmonary hypertension and certain cancers. Its portfolio spans marketed medicines and pipeline programs, and it generated $3.2 billion of revenue in FY2025.

Name
United Therapeutics Corporation
CEO
Martine A. Rothblatt
Industry
Healthcare
Year Founded
1996
Employees
1,400

Today's Snapshot

AI-generated

UTHR closed 1.2% below yesterday's close, in line with a weaker sector.

Trading Volume

Below 10d avg (457.6K)

416.3K

vs S&P 500 Today

Underperforming Market

-0.90%

Updated: November 18, 2026 at 21:30 UTC

Technical Indicators

3 Buy3 Neutral2 Sell
UTHR shows a neutral technical profile as modest short-term weakness is offset by longer-term moving average support. Momentum indicators are mixed: RSI sits near neutral and MACD is mildly positive while short-term momentum reads negative, which aligns with prices trading slightly below the classic pivot near 583. Short and medium EMAs sit above the current price but the 50–200 day averages remain supportive, and ADX indicates a weak trend. Volatility is moderate with an ATR around $18 and OBV points to recent outflows. Technical takeaway: Neutral — balanced short-term caution against longer-term support.
All signals
  • EMA (5 indicators)$534.49 - $585.25
    Buy
  • RSI (14)51.25
    Neutral
  • Stochastic %K (14, 3, 3)45.97
    Neutral
  • MACD Level (12, 26)9.30
    Neutral
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.